Soleno Therapeutics to Participate in Upcoming Investor Conferences

Published

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

EventJefferies Global Healthcare Conference
DayWednesday, June 5, 2024
Time:11:30 AM Eastern Time
  
Event:Goldman Sachs 45th Annual Global Healthcare Conference
Day:Tuesday, June 11, 2024
Time:4:00 PM ET
  

A live audio webcast and replay of the events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

Primary Logo

Source: Soleno Therapeutics

In This Story

SLNO